EC Ophthalmology

Case Report Volume 14 Issue 3 - 2023

Keratoplasty, Immunosuppressors and SARS-CoV-19

Victoria Myasnikova1*, Sergey Sakhnov1, Denis Nefedov1, Ekaterina Afonina1, Tamriko Zakaraiia2 and Shu Ruset1

1Krasnodar Branch of the S.N. Fedorov NMRC MNTK Eye Microsurgery, Krasnodar, Russia
2Saint-Petersburg Branch of the S.N. Fedorov NMRC MNTK Eye Microsurgery, Saint-Petersburg, Russia

*Corresponding Author: Victoria Myasnikova, Krasnodar Branch of the S.N. Fedorov NMRC MNTK Eye Microsurgery, Krasnodar, Krasnodarskiy Kray, Russia.
Received: January 31, 2023; Published: February 22, 2023



We report a case of a successful outcome of keratoplasty in a keratoconus patient with an episode of coronavirus disease 2019 (COVID-19) in the postoperative period. 

Keywords: Keratoconus Corneal Transplantation; SARS-CoV; Immunosuppressants Graft Rejection; COVID-19 Pandemic

  1. Eye Bank Association of America. 2020 Eye Banking Statistical Report.
  2. Casagrande M., et al. “Presence of SARS-CoV-2 RNA in the Cornea of Viremic Patients With COVID-19”. JAMA Ophthalmology 4 (2021): 383-388.
  3. Barraquer RI., et al. “Risk factors for graft failure after penetrating keratoplasty”. Medicine17 (2019): e15274.
  4. Jin SX and Juthani VV. “Acute Corneal Endothelial Graft Rejection with Coinciding COVID-19 Infection”. Cornea 1 (2021): 123-124.
  5. Phylactou M., et al. “Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine”. British Journal of Ophthalmology7 (2021): 893-896.
  6. Singh G and Mathur U. “Acute graft rejection in a COVID-19 patient”. Indian Journal of Ophthalmology4 (2021): 985-986.
  7. Andersen KM., et al. “Association Between Chronic Use of Immunosuppresive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System”. Clinical Infectious Diseases 11 (2021): ciaa1488.
  8. Periman LM., et al. “A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments”. Clinical Ophthalmology 14 (2020): 4187-4200.
  9. Utine CA., et al. “Clinical review: topical ophthalmic use of cyclosporin A”. Ocular Immunology and Inflammation 5 (2010): 352-361.
  10. Thng ZX., et al. “COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs”. British Journal of Ophthalmology 3 (2021): 306-310.

Victoria Myasnikova., et al. Keratoplasty, Immunosuppressors and SARS-CoV-19. EC Ophthalmology 14.3 (2023): 13-18.